Genome-Wide Transcriptional Effects of the Anti-Cancer Agent Camptothecin

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Veloso, Artur ^a,b   Biewen, Benjamin ^a,c   Paulsen, Michelle T ^a   Berg, Nathan ^a   Carmo de Andrade Lima, Leonardo ^a,d   Prasad, Jayendra ^a   Bedi, Karan ^a,e   Magnuson, Brian ^a   Wilson, Thomas E ^b   Ljungman, Mats ^a,e  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c GUSTAVUS ADOLPHUS COLLEGE   (United States)

^d UNIVERSITY OF SÃO PAULO   (Brazil)

^e UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAMPTOTHECIN; PROTEIN P53; RNA; RNA POLYMERASE; ANTINEOPLASTIC AGENT; DNA HELICASE; DNA TOPOISOMERASE; ERCC6 PROTEIN, HUMAN; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; TOP1 PROTEIN, HUMAN;

ANTI APOPTOTIC GENE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DNA REPAIR; DRUG DESIGN; ENHANCER REGION; FIBROBLAST CULTURE; GENE; GENE EXPRESSION REGULATION; GENE TARGETING; GENETIC TRANSCRIPTION; GENOME ANALYSIS; GENOME SIZE; HUMAN; HUMAN CELL; MALE; PRO APOPTOTIC GENE; PROTO ONCOGENE; RNA SYNTHESIS; SEQUENCE ANALYSIS; SMALLER RIBOSOMAL PROTEIN GENE; TRANSCRIPTION ELONGATION; TRANSCRIPTION TERMINATION; DNA SEQUENCE; DRUG EFFECTS; FIBROBLAST; GENE LIBRARY; GENETICS; GENOME; METABOLISM; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BASE SEQUENCE; CAMPTOTHECIN; DNA HELICASES; DNA REPAIR ENZYMES; DNA TOPOISOMERASES, TYPE I; FIBROBLASTS; GENE LIBRARY; GENOME; HUMANS; MOLECULAR SEQUENCE DATA; SEQUENCE ANALYSIS, DNA; TRANSCRIPTION ELONGATION, GENETIC;

EID: 84886035644     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0078190     Document Type: Article

References (28)

1. Liu LF, Wang JC, (1987) Supercoiling of the DNA template during transcription. Proc Natl Acad Sci U S A 84: 7024-7027. doi:10.1073/pnas.84.20.7024. PubMed: 2823250.
2. Pommier Y, (2006) Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer 6: 789-802. doi:10.1038/nrc1977. PubMed: 16990856.
3. Hsiang Y-H, Liu LF, (1988) Identification of mammalian topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res 48: 1722-1726. PubMed: 2832051.
4. Pommier Y, (2013) Drugging topoisomerases: lessons and challenges. ACS Chem Biol 8: 82-95. doi:10.1021/cb300648v. PubMed: 23259582.
5. Hsiang Y-H, Lihou MG, Liu LF, (1989) Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 49: 5077-5082. PubMed: 2548710.
6. Wu JX, Liu LF, (1997) Processing of topoisomerase I cleavable complexes into DNA damage by transcription. Nucleic Acids Res 25: 4181-4186. doi:10.1093/nar/25.21.4181. PubMed: 9336444.
7. Sordet O, Redon CE, Guirouilh-Barbat J, Smith S, Solier S, et al. (2009) Ataxia telangiectasia mutated activation by transcription- and topoisomerase I-induced DNA double-strand breaks. EMBO Rep 10: 887-893. doi:10.1038/embor.2009.97. PubMed: 19557000.
8. Ljungman M, Hanawalt PC, (1996) The anti-cancer drug camptothecin inhibits elongation but stimulates initiation of RNA polymerase II transcription. Carcinogenesis 17: 31-35. doi:10.1093/carcin/17.1.31. PubMed: 8565133.
9. Desai SD, Liu LF, Vazquez-Abad D, D'Arpa P, (1997) Ubiquitin-dependent destruction of topoisomerase I is stimulated by the antitumor drug camptothecin. J Biol Chem 272: 24159-24164. doi:10.1074/jbc.272.39.24159. PubMed: 9305865.
10. Plo I, Liao ZY, Barceló JM, Kohlhagen G, Caldecott KW, et al. (2003) Association of XRCC1 and tyrosyl DNA phosphodiesterase (Tdp1) for the repair of topoisomerase I-mediated DNA lesions. DNA Repair (Amst) 2: 1087-1100. doi:10.1016/S1568-7864(03)00116-2. PubMed: 13679147.
11. Sakasai R, Teraoka H, Takagi M, Tibbetts RS, (2010) Transcription-dependent activation of ataxia telangiectasia mutated prevents DNA-dependent protein kinase-mediated cell death in response to topoisomerase I poison. J Biol Chem 285: 15201-15208. doi:10.1074/jbc.M110.101808. PubMed: 20304914.
12. Ljungman M, O'Hagan HM, Paulsen MT, (2001) Induction of ser15 and lys382 modifications of p53 by blockage of transcription elongation. Oncogene 20: 5964-5971. doi:10.1038/sj.onc.1204734. PubMed: 11593403.
13. Ljungman M, Zhang FF, Chen F, Rainbow AJ, McKay BC, (1999) Inhibition of RNA polymerase II as a trigger for the p53 response. Oncogene 18: 583-592. doi:10.1038/sj.onc.1202356. PubMed: 9989808.
14. Ljungman M, Lane DP, (2004) Transcription- guarding the genome by sensing DNA damage. Nat Rev Cancer 4: 727-737. doi:10.1038/nrc1435. PubMed: 15343279.
15. Lin RK, Ho CW, Liu LF, Lyu YL, (2013) Topoisomerase IIbeta deficiency enhances camptothecin-induced apoptosis. J Biol Chem 288: 7182-7192. doi:10.1074/jbc.M112.415471. PubMed: 23344961.
16. Sakai A, Sakasai R, Kakeji Y, Kitao H, Maehara Y, (2012) PARP and CSB modulate the processing of transcription-mediated DNA strand breaks. Genes Genet Syst 87: 265-272. PubMed: 23229313.
17. Horibata K, Saijo M, Bay MN, Lan L, Kuraoka I, et al. (2011) Mutant Cockayne syndrome group B protein inhibits repair of DNA topoisomerase I-DNA covalent complex. Genes Cells 16: 101-114. doi:10.1111/j.1365-2443.2010.01467.x. PubMed: 21143350.
18. Squires S, Ryan AJ, Strutt HL, Johnson RT, (1993) Hypersensitivity of Cockayne's syndrome cells to camptothecin is associated with the generation of abnormally high levels of double strand breaks in nascent DNA. Cancer Res 53: 2012-2019. PubMed: 7683249.
19. Paulsen MT, Veloso A, Prasad J, Bedi K, Ljungman EA, et al. (2013) Coordinated regulation of synthesis and stability of RNA during the acute TNF-induced proinflammatory response. Proc Natl Acad Sci U S A 110: 2240-2245. doi:10.1073/pnas.1219192110. PubMed: 23345452.
20. Durand-Dubief M, Svensson JP, Persson J, Ekwall K, (2011) Topoisomerases, chromatin and transcription termination. Transcription 2: 66-70. doi:10.4161/trns.2.2.14411. PubMed: 21468231.
21. Preker P, Nielsen J, Kammler S, Lykke-Andersen S, Christensen MS, et al. (2008) RNA exosome depletion reveals transcription upstream of active human promoters. Science 322: 1851-1854. doi:10.1126/science.1164096. PubMed: 19056938.
22. Danko CG, Hah N, Luo X, Martins AL, Core L, et al. (2013) Signaling pathways differentially affect RNA polymerase II initiation, pausing, and elongation rate in cells. Mol Cell 50: 212-222. doi:10.1016/j.molcel.2013.02.015. PubMed: 23523369.
23. McKay BC, Stubbert LJ, Fowler CC, Smith JM, Cardamore RA, et al. (2004) Regulation of ultraviolet light-induced gene expression by gene size. Proc Natl Acad Sci U S A 101: 6582-6586. doi:10.1073/pnas.0308181101. PubMed: 15087501.
24. Nitiss J, Wang JC, (1988) DNA topoisomerase-targeting antitumor drugs can be studied in yeast. Proc Natl Acad Sci U S A 85: 7501-7505. doi:10.1073/pnas.85.20.7501. PubMed: 2845409.
25. Chen AY, Choy H, Rothenberg ML, (1999) DNA topoisomerase I-targeting drugs as radiation sensitizers. Oncology 13: 39-46. PubMed: 10550825.
26. Bowman KJ, Newell DR, Calvert AH, Curtin NJ, (2001) Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro. Br J Cancer 84: 106-112. doi:10.1054/bjoc.2000.1555. PubMed: 11139322.
27. Zhang YW, Regairaz M, Seiler JA, Agama KK, Doroshow JH, et al. (2011) Poly(ADP-ribose) polymerase and XPF-ERCC1 participate in distinct pathways for the repair of topoisomerase I-induced DNA damage in mammalian cells. Nucleic Acids Res 39: 3607-3620. doi:10.1093/nar/gkq1304. PubMed: 21227924.
28. Solier S, Ryan MC, Martin SE, Varma S, Kohn KW, et al. (2013) Transcription Poisoning by Topoisomerase I Is Controlled by Gene Length, Splice Sites, and miR-142-3p. Cancer Res 73: 4830-4839. doi:10.1158/0008-5472.CAN-12-3504. PubMed: 23786772.